{
    "clinical_study": {
        "@rank": "146298", 
        "arm_group": {
            "arm_group_label": "E1", 
            "arm_group_type": "Experimental", 
            "description": "[14C]-ONO-4053"
        }, 
        "brief_summary": {
            "textblock": "This is a single dose mass balance study in healthy adult male volunteers to investigate the\n      metabolism and excretion of [14C]-ONO-4053."
        }, 
        "brief_title": "A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053", 
        "condition": "Healthy Adult Male Subjects", 
        "detailed_description": {
            "textblock": "This is a single centre, open-label, non-randomised study in healthy adult male subjects.\n      Six subjects will receive a single dose of 14C ONO-4053 administered orally as a suspension.\n      Safety measurements (ECG, vital signs, biochemistry and haematology) and adverse events will\n      be monitored throughout the study.  After administration of 14C ONO-4053 subjects will\n      remain in the clinical facility for collection of blood, urine and faecessamples. Samples\n      will be analysed for recovery of radioactivity and characterisation of metabolites of\n      ONO-4053."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject has provided written informed consent\n\n          2. Healthy male subjects aged 35 to 65 years inclusive\n\n          3. Subject is not trying to father a child and is willing to use one of the\n             contraception methods listed in the protocol 4 The subject has a body mass index of\n             19.0 to 30.0 kg/m2 inclusive. 5 The subject is healthy as determined by the\n             Investigator 6 Regular daily bowel movements\n\n        Exclusion Criteria:\n\n          1. The Investigator deems the subject unsuitable for the study\n\n          2. The subject has, or has a history of, any significant disease or disorder (including\n             any clinically significant laboratory findings) that would increase the risk for the\n             subject if they were enrolled in the study\n\n          3. The subject has a history of acute gastrointestinal illness\n\n          4. The subject has used prescription medicine, non-prescription medicine, vitamins,\n             herbal treatments or dietary supplements within 14 days of dosing.\n\n          5. Current smokers and those who have smoked within the last 12 months\n\n          6. Radiation exposure, including that from the present study, excluding background\n             radiation but including diagnostic x-rays and other medical exposures, exceeding 5\n             mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed\n             worker, as defined in the Ionising Radiation Regulations 1999, shall participate in\n             the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909986", 
            "org_study_id": "ONO-4053POE004"
        }, 
        "intervention": {
            "arm_group_label": "E1", 
            "description": "Single dose [14C]ONO-4053", 
            "intervention_name": "[14C]ONO-4053", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ONO-4053", 
            "Healthy adult male subjects", 
            "pharmacokinetics", 
            "metabolism", 
            "excretion", 
            "mass balance"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Nottingham Clinical site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Single-dose Study to Evaluate the Pharmacokinetics, Metabolism and Excretion Balance of [14C]-ONO-4053 in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Clinical Department", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Total recovery of radioactivity in urine and faeces expressed as a percentage of the total radioactive dose administered", 
            "measure": "[14C]ONO-4053 recovery", 
            "safety_issue": "No", 
            "time_frame": "11 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterisation and identification of [14C]-ONO-4053 metabolites in plasma, urine and faeces.", 
                "measure": "[14C]-ONO-4053 metabolites", 
                "safety_issue": "No", 
                "time_frame": "11 Days"
            }, 
            {
                "description": "PK parameters of total drug-related material (radioactivity) in blood and plasma", 
                "measure": "Total drug-related material", 
                "safety_issue": "No", 
                "time_frame": "11 Days"
            }, 
            {
                "description": "PK parameters of ONO-4053 in plasma", 
                "measure": "ONO-4053 in plasma", 
                "safety_issue": "No", 
                "time_frame": "11 Days"
            }, 
            {
                "description": "Blood:plasma ratio of total drug-related material (radioactivity)", 
                "measure": "Blood:plasma ratio of [14C]ONO-4053", 
                "safety_issue": "No", 
                "time_frame": "11 Days"
            }, 
            {
                "description": "PK parameter of total radioactivity in urine", 
                "measure": "Radioactivity in urine", 
                "safety_issue": "No", 
                "time_frame": "11 Days"
            }, 
            {
                "description": "Safety and tolerability parameters including collection of adverse events, physical examinations, vital signs, 12-Lead ECG and laboratory evaluations.", 
                "measure": "Safety and tolerability parameters", 
                "safety_issue": "Yes", 
                "time_frame": "14 - 16 days"
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}